SlowBull
The market, slowly. THURSDAY, 24 SEPTEMBER 2026
← All news
Markets

Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute

1 source ·1 article ·Sep 2, 14:12 UTC GSK

Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·Sep 2, 14:12 UTC

Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute

Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.